MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-16-2023
Athersys Retained Earnings 2011-2026 | ATHX
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Athersys
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -583 M | -496 M | -418 M | -373 M | -351 M | -318 M | -303 M | -287 M | -264 M | -234 M | -219 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -219 M | -583 M | -350 M |
Quarterly Retained Earnings Athersys
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -680 M | -677 M | -664 M | -656 M | -643 M | -629 M | -606 M | -583 M | -562 M | -545 M | -523 M | -496 M | -496 M | -496 M | -496 M | -418 M | -418 M | -418 M | -418 M | -373 M | -373 M | -373 M | -373 M | -351 M | -351 M | -351 M | -351 M | -318 M | -318 M | -318 M | -318 M | -303 M | -303 M | -303 M | -303 M | -287 M | -287 M | -287 M | -287 M | -264 M | -264 M | -264 M | -264 M | -234 M | -234 M | -234 M | -234 M | -219 M | -219 M | -219 M | -219 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -219 M | -680 M | -389 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
-903 M | $ 2.63 | -2.05 % | $ 203 M |  USA |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 211.71 | -0.74 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.27 | 1.87 % | $ 7.87 B |  Australia |
 |
Autolus Therapeutics plc
AUTL
|
-1.1 B | $ 1.89 | -3.08 % | $ 482 M |  Britain |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-972 M | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-2.12 B | - | -6.81 % | $ 3.04 B | USA |
 |
Avenue Therapeutics
ATXI
|
-103 M | - | -52.27 % | $ 4.45 M | USA |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.02 B | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
-410 M | $ 99.5 | -0.58 % | $ 27.2 B | Germany |
 |
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
569 M | $ 28.01 | 2.47 % | $ 1.36 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-166 M | $ 4.41 | -6.57 % | $ 9.6 B |  Israel |
 |
AVROBIO
AVRO
|
-477 M | - | 1083.1 % | $ 745 M | USA |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 11.04 | 0.91 % | $ 727 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-8.61 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-2.59 B | $ 11.09 | -5.62 % | $ 717 M | USA |
 |
BioVie
BIVI
|
-352 M | $ 1.3 | -4.07 % | $ 1.92 M | USA |
 |
Axon Enterprise
AXON
|
812 M | $ 617.73 | -0.51 % | $ 46.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.66 | -6.01 % | $ 16.7 M | USA |
 |
AstraZeneca PLC
AZN
|
5.3 B | $ 95.28 | 0.13 % | $ 96.9 B | Britain |
 |
Bellicum Pharmaceuticals
BLCM
|
-575 M | - | -9.72 % | $ 5.89 M | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Berkeley Lights
BLI
|
-362 M | - | -7.31 % | $ 87 M | USA |
 |
Brickell Biotech
BBI
|
-172 M | - | -5.38 % | $ 6.06 M | USA |
 |
bluebird bio
BLUE
|
-4.26 B | - | - | $ 546 M | USA |
 |
Biogen
BIIB
|
19.3 B | $ 185.85 | -0.57 % | $ 27.1 B | USA |
 |
Abeona Therapeutics
ABEO
|
-750 M | $ 5.06 | -3.07 % | $ 108 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-113 M | $ 1.46 | - | $ 16.7 M | Israel |
 |
Cellectis S.A.
CLLS
|
-506 M | $ 4.5 | -1.1 % | $ 116 M | France |